Natco Pharma today announced the launch of the first generic version of Sofosbuvir 400mg/Velpatasvir 100 mg fixed dose combination in Nepal. Sofosbuvir 400mg/Velpatasvir 100 mg fixed dose combination is sold by Gilead Sciences, Inc., under the brandname Epclusa®. Epclusa® is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.
Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for Ribavirin. Natco will market Sofosbuvir 400mg/Velpatasvir 100mg under the brand name VELPANAT.
The Hyderabad-based firm has priced its generic medicine of ‘Velpanat’ at ₹25,000 equivalent for a bottle of 28 tablets in Nepal. Natco has signed a non-exclusive licensing agreement with Gilead Sciences to manufacture and sell generic versions of its Hep C medicines in 101 developing countries.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.